oral non-peptide GLP-1R GPCR partial agonist
in Ph. I for Type 2 diabetes, HV study complete
from cell-based screen and opt.
PNAS, Nov. 11, 2020
Chugai, Shizuoka, JP / Eli Lilly, Indianapolis, IN
Chugai/Lilly clinical oral non-peptide GLP-1R GPCR partial agonist